Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRELUDE: Enzastaurin for Prevention of Relapse in DLBCL
NCT00332202Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2006
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of enzastaurin in diffuse large B-cell lymphoma (DLBCL), sponsored by Eli Lilly and Company. Started Jun 2006; status: completed.
02
Drugs
enzastaurin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00332202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332202.